[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bridgebio Pharma Inc (BBIO)

Bridgebio Pharma Inc (BBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,221,510
  • Shares Outstanding, K 195,487
  • Annual Sales, $ 502,080 K
  • Annual Income, $ -724,930 K
  • EBIT $ -498 M
  • EBITDA $ -486 M
  • 60-Month Beta 0.96
  • Price/Sales 31.11
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 47.43% (+2.99%)
  • Historical Volatility 51.23%
  • IV Percentile 14%
  • IV Rank 15.50%
  • IV High 80.30% on 02/05/26
  • IV Low 41.40% on 08/14/26
  • Expected Move (DTE 2) 3.02 (3.55%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 422
  • Volume Avg (30-Day) 532
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 42,605
  • Open Int (30-Day) 41,169
  • Expected Range 82.08 to 88.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.67
  • Number of Estimates 8
  • High Estimate $-0.38
  • Low Estimate $-0.90
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +29.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
78.13 +7.62%
on 08/17/26
89.49 -6.05%
on 08/11/26
+2.70 (+3.32%)
since 07/17/26
3-Month
62.50 +34.53%
on 06/02/26
93.42 -9.99%
on 07/09/26
+18.08 (+27.39%)
since 05/19/26
52-Week
46.81 +79.62%
on 08/25/25
93.42 -9.99%
on 07/09/26
+35.17 (+71.91%)
since 08/19/25

Most Recent Stories

More News
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownership PALO ALTO, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma,...

BBIO : 84.44 (+1.76%)
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines...

BBIO : 84.44 (+1.76%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 84.44 (+1.76%)
BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma: Q2 Earnings Snapshot

BBIO : 84.44 (+1.76%)
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates

- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly...

BBIO : 84.44 (+1.76%)
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET

PALO ALTO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 84.44 (+1.76%)
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1

- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential...

BBIO : 84.44 (+1.76%)
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

AZN : 164.41 (+2.69%)
ALNY : 239.46 (+4.75%)
IONS : 60.74 (+1.88%)
BBIO : 84.44 (+1.76%)
PFE : 28.31 (+3.89%)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic...

BBIO : 84.44 (+1.76%)
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P...

BBIO : 84.44 (+1.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif.

See More

Key Turning Points

3rd Resistance Point 88.44
2nd Resistance Point 86.19
1st Resistance Point 84.59
Last Price 84.47
1st Support Level 80.74
2nd Support Level 78.49
3rd Support Level 76.89

See More

52-Week High 93.42
Last Price 84.44
Fibonacci 61.8% 75.61
Fibonacci 50% 70.11
Fibonacci 38.2% 64.61
52-Week Low 46.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.